- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05416840
Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension (ECLIPSE)
Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension: a Randomized Controlled Trial (ECLIPSE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jing Liu, MD
- Phone Number: 01088325457
- Email: heartcenter@163.com
Study Locations
-
-
-
Beijing, China, 100044
- Peking University People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-60 years old male with mild hypertension (systolic blood pressure (BP) 140-159 mmHg and/or diastolic BP 90-99 mmHg).
- History of smoking and a desire to quit.
- Signed informed consent form.
Exclusion Criteria:
- History of cardiopulmonary and vascular disease.
- Severe liver or kidney disease.
- Night shift workers, drivers, and those who work at height.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clonidine
Patients will receive clonidine controlled-release patch (2.5 mg), once a week
|
Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (<140 mmHg) at 4 weeks. All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6). |
Active Comparator: Amlodipine
Patients will receive amlodipine (5 mg), once daily
|
Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (<140 mmHg) at 4 weeks. All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in clinic sitting systolic BP from baseline at 8-week
Time Frame: 8 weeks
|
The change in clinic sitting systolic BP from baseline at 8-week in clonidine group and amlodipine group are analyzed, and between groups difference is compared.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in systolic BP in 24 hour ambulatory BP monitoring (ABPM) from baseline at 8-week
Time Frame: 8 weeks
|
The change in systolic BP in 24 hour ambulatory BP monitoring (ABPM) from baseline at 8-week in clonidine group and amlodipine group are analyzed, and between groups differences are compared.
|
8 weeks
|
Between-group differences in smoking cessation rates at 8-week
Time Frame: 8 weeks
|
Between-group differences in smoking cessation rates at 8-week in clonidine group and amlodipine are compared
|
8 weeks
|
Drug tolerance and adverse effects during 8 weeks of treatment
Time Frame: 8 weeks
|
Drug tolerance and adverse effects during 8 weeks of treatment, clonidine or amlodipine, are analyzed
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jing Liu, MD, Peking University People's Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Sympatholytics
- Amlodipine
- Clonidine
Other Study ID Numbers
- 20220001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Clonidine controlled-release patch
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
PfizerCompletedHealthy SubjectsUnited States
-
PfizerWithdrawn
-
University Hospital Bispebjerg and FrederiksbergNot yet recruitingHypoxic Respiratory Failure | Ventilators, MechanicalDenmark
-
University of California, Los AngelesNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Addrenex Pharmaceuticals, Inc.CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Afshan B. Hameed, M.D.Withdrawn
-
University of Tennessee, ChattanoogaWithdrawnAcute Lung Injury | Kidney Injury | Adult Respiratory Distress SyndromeUnited States
-
Purdue Pharma LPCompleted
-
Mahidol UniversityNot yet recruiting